文献速递淋巴瘤

淋巴瘤微小残留病评估:方法与临床应用

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
PubMed 文献 · J Clin Oncol · 2017-09-21

综述指出,淋巴瘤常规影像学疗效评估不完美,而微小残留病(MRD)检测在白血病中已影响治疗范式,但在淋巴瘤中因缺乏易检测的循环病灶或典型染色体易位而应用受限。基于二代测序的新MRD方法在多种淋巴瘤亚型中显示有前景的结果,MRD评估可提供肿瘤负荷、疗效、无创基因组分析和克隆动态信息,需进一步验证并纳入临床试验。

要点

  • 常规PET/CT评估淋巴瘤疗效并不完美。
  • 流式细胞术或PCR检测MRD在多种淋巴瘤亚型中因缺乏易检测的循环病灶或典型染色体易位而具挑战性。
  • 基于二代测序的新MRD检测方法在多种淋巴瘤亚型中显示有前景的结果。

核心结论

  • 基于二代测序的MRD检测在多种淋巴瘤亚型中显示有前景的结果,燃起了MRD检测可能很快适用于大多数淋巴瘤患者临床实践的希望。
  • 需进一步验证MRD评估方法并将MRD评估纳入淋巴瘤临床试验,以确定如何在常规实践中最佳部署MRD检测以及MRD评估最终能否更接近个体化淋巴瘤诊疗的目标。

研究设计与样本

  • 综述文章,描述可用于检测淋巴瘤患者MRD的方法及其相对优缺点,并讨论支持MRD检测在淋巴瘤诊疗中潜在应用的初步结果以及将MRD评估纳入淋巴瘤临床试验的策略。

主要发现

  • 淋巴瘤常规疗效评估方法包括正电子发射断层扫描和计算机断层扫描,并不完美。
  • 在白血病等其他血液系统恶性肿瘤中,检测MRD的能力日益影响治疗范式。
  • 在许多淋巴瘤亚型中,流式细胞术或基于聚合酶链反应的方法等MRD评估技术的应用因缺乏易检测的循环病灶或典型染色体易位而具挑战性。
  • MRD评估可提供关于肿瘤负荷和治疗反应的实时信息、无创基因组分析以及克隆动态监测。
  • 基于二代测序的新MRD检测方法在多种淋巴瘤亚型中已产生有前景的结果。

临床怎么用

  • MRD评估可提供实时肿瘤负荷和疗效信息、无创基因组分析及克隆动态监测,具有可能显著影响淋巴瘤患者诊疗的多种潜在应用。

局限性

  • 需进一步验证MRD评估方法,包括将MRD评估纳入淋巴瘤患者临床试验,以确定如何在常规实践中最佳部署MRD检测以及MRD评估最终能否更接近个体化淋巴瘤诊疗的目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standard methods for disease response assessment in patients with lymphoma, including positron emission tomography and computed tomography scans, are imperfect. In other hematologic malignancies, particularly leukemias, the ability to detect minimal residual disease (MRD) is increasingly influencing treatment paradigms. However, in many subtypes of lymphoma, the application of MRD assessment techniques, like flow cytometry or polymerase chain reaction-based methods, has been challenging because of the absence of readily detected circulating disease or canonic chromosomal translocations. Newer MRD detection methods that use next-generation sequencing have yielded promising results in a number of lymphoma subtypes, fueling the hope that MRD detection may soon be applicable in clinical practice for most patients with lymphoma. MRD assessment can provide real-time information about tumor burden and response to therapy, noninvasive genomic profiling, and monitoring of clonal dynamics, allowing for many possible applications that could significantly affect the care of patients with lymphoma. Further validation of MRD assessment methods, including the incorporation of MRD assessment into clinical trials in patients with lymphoma, will be critical to determine how best to deploy MRD testing in routine practice and whether MRD assessment can ultimately bring us closer to the goal of personalized lymphoma care. In this review article, we describe the methods available for detecting MRD in patients with lymphoma and their relative advantages and disadvantages. We discuss preliminary results supporting the potential applications for MRD testing in the care of patients with lymphoma and strategies for including MRD assessment in lymphoma clinical trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Herrera AF, Armand P. Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol. 2017. PMID: 28933999. doi:10.1200/JCO.2017.74.5281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。